Galderma Secures €500M Eurobond in Strategic Refinancing Move
Event summary
- Galderma placed a €500M Eurobond on March 10, 2026 with a 5-year maturity and 3.375% annual coupon.
- Proceeds will fully repay the company’s existing bank term loan from its 2024 IPO.
- The transaction completes Galderma’s refinancing process, leveraging its investment-grade credit ratings (BBB).
- Bond is expected to be listed on the SIX Swiss Exchange by March 17, 2026.
The big picture
Galderma’s €500M Eurobond issuance marks the final step in a strategic refinancing initiative, replacing higher-cost IPO debt with lower-rate capital. The move underscores the company’s disciplined financial governance amid a competitive dermatology market, where scale and operational efficiency are key differentiators. With investment-grade backing, Galderma solidifies its position as a pure-play leader while maintaining flexibility for future growth investments.
What we're watching
- Debt Management
- How Galderma’s lower-cost Eurobond affects its net financial expenses in 2026.
- Credit Outlook
- Whether S&P’s positive outlook on Galderma’s BBB rating will be upheld post-refinancing.
- Market Positioning
- The pace at which Galderma deploys proceeds to strengthen its dermatology portfolio leadership.
Related topics